1. Pink Sheet

Priority Review Vouchers: Buyers Beware!

 
• By Michael McCaughan

The recent series of sales of priority review vouchers at ever-higher prices has transformed what had seemed to be a failed incentive model into a hot topic. However, one key stakeholder is not celebrating the recent developments: the FDA review teams that have to deliver the faster paced reviews continue to have strong reservations about the program.

The value placed on priority review vouchers hit a new high with AbbVie Inc.’s August 19 agreement to pay $350 million for United Therapeutics Corp.’s PRV.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet